J&J's Janssen, Legend Get CHMP Backing for Carvykti Blood Cancer Drug
25 March 2022 - 11:49PM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit and
Legend Biotech Corp. on Friday said the European Medicines Agency's
Committee for Medicinal Products for Human Use recommended approval
of their cell-based therapy Carvykti for certain patients with the
blood cancer multiple myeloma.
The companies said the recommendation covers Carvykti for the
treatment of adults with relapsed and refractory multiple myeloma
who have received at least three prior therapies and have shown
disease progression on the last therapy.
Janssen and Legend, a Somerset, N.J.-based biotechnology
company, in late 2017 struck an exclusive world-wide license and
collaboration agreement to develop and commercialize Carvykti.
The U.S. Food and Drug Administration last month approved
Carvykti, making it the first customized, cell-based treatment in
the U.S. to be developed initially in China.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 25, 2022 08:34 ET (12:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024